JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Начало・Списък с акции・Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

11.88 2.5

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

11.79

Максимум

11.88

Ключови измерители
By Trading Economics
Приходи	-1.8M 22M
Продажби	7.5M 70M
P/E Средно за сектора	27.535 37.461
Марж на печалбата	30.729
Служители	130
EBITDA	6.3M 28M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	-1.85% downside

Дивиденти
By Dow Jones
Следващи печалби	6.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	357M 1.6B
Предишно отваряне	9.38
Предишно затваряне	11.88

Настроения в новините

By Acuity

50%

147 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

8.1 / 8.21 Подкрепа & съпротива

Aurinia Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.10.2025 г., 18:41 ч. UTC

Печалби

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24.10.2025 г., 18:31 ч. UTC

Печалби

Correction to Procter & Gamble to Focus on Innovation

24.10.2025 г., 16:25 ч. UTC

Значими двигатели на пазара

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24.10.2025 г., 21:24 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

24.10.2025 г., 21:24 ч. UTC

Пазарно говорене

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24.10.2025 г., 21:07 ч. UTC

Печалби

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24.10.2025 г., 20:58 ч. UTC

Печалби

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

24.10.2025 г., 20:40 ч. UTC

Печалби

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24.10.2025 г., 20:24 ч. UTC

Печалби

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24.10.2025 г., 20:23 ч. UTC

Печалби

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24.10.2025 г., 20:13 ч. UTC

Печалби

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24.10.2025 г., 20:07 ч. UTC

Пазарно говорене

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24.10.2025 г., 19:40 ч. UTC

Пазарно говорене

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24.10.2025 г., 19:35 ч. UTC

Пазарно говорене

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24.10.2025 г., 19:33 ч. UTC

Печалби

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24.10.2025 г., 19:29 ч. UTC

Пазарно говорене

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24.10.2025 г., 18:52 ч. UTC

Печалби

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24.10.2025 г., 18:41 ч. UTC

Печалби

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24.10.2025 г., 18:03 ч. UTC

Печалби

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24.10.2025 г., 18:02 ч. UTC

Печалби

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24.10.2025 г., 18:00 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24.10.2025 г., 16:57 ч. UTC

Печалби

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24.10.2025 г., 16:54 ч. UTC

Пазарно говорене

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24.10.2025 г., 16:44 ч. UTC

Пазарно говорене

Печалби

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24.10.2025 г., 16:39 ч. UTC

Пазарно говорене

Печалби

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24.10.2025 г., 16:33 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24.10.2025 г., 16:23 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

24.10.2025 г., 16:07 ч. UTC

Печалби

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Aurinia Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

-1.85% надолу

12-месечна прогноза

Среден 11.67 USD -1.85%

Висок 17 USD

Нисък 9 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Aurinia Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Aurinia Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

8.1 / 8.21Подкрепа & съпротива

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bullish event.

Настроение

By Acuity

147 / 371 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.